AbbVie Expands its Collaboration with Capsida Biotherapeutics to Develop Targeted Genetic Therapies for Eye Diseases
- Under the expanded agreement, Capsida will receive $70M up front & equity investment, ~$595M in option fees, research & development milestones for 3 programs & commercial milestones along with royalty on future product sales
- The agreement will combine AbbVie's extensive capabilities with Capsida's novel adeno-associated virus (AAV) engineering platform & manufacturing capability to advance 3 programs
- Capsida will be responsible for capsid discovery efforts for all programs using high throughput AAV engineering platform & will lead the process development and early clinical manufacturing while AbbVie will lead innovative therapeutic cargo approaches along with development and commercialization
Ref: PRNewswire | Image: Abbvie
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.